Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Noncovalent wild-type-sparing inhibitors of EGFR T790M.

Cancer discovery - 1 Feb 2013

Lee Ho-June, Schaefer Gabriele, Heffron Timothy P, Shao Lily, Ye Xiaofen, Sideris Steve, Malek Shiva, Chan Emily, Merchant Mark, La Hank, Ubhayakar Savita, Yauch Robert L, Pirazzoli Valentina, Politi Katerina, Settleman Jeff

Abstract excerpt

UNLABELLED: Approximately half of EGFR-mutant non-small cell lung cancer (NSCLC) patients treated with small-molecule EGFR kinase inhibitors develop drug resistance associated with the EGF receptor (EGFR) T790M "gatekeeper" substitution, prompting efforts to develop covalent EGFR inhibitors, which can effectively suppress EGFR T790M in preclinical models. However, these inhibitors have yet to prove clinically...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Area Under Curve

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carbazoles

Share to Erlotinib Hydrochloride

Share to Pyrimidines

Share to Quinazolines

Share to Staurosporine

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 23229345
DOI: 10.1158/2159-8290.CD-12-0357
PMCID: PMC3576842

Genes

EGFR
EGF
FLT3

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Noncovalent wild-type-sparing inhibitors of EGFR T790M.PMID 23229345Read ↗

Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor.Semantic proximity Read ↗

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.Semantic proximity Read ↗

Discovery of selective irreversible inhibitors for EGFR-T790M.Semantic proximity Read ↗

Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.Semantic proximity Read ↗

Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.Semantic proximity Read ↗

Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Discovery and optimization of covalent EGFR T790M/L858R mutant inhibitors.Semantic proximity Read ↗

Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLCSemantic proximity Read ↗

In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing.Semantic proximity Read ↗

Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance.Semantic proximity Read ↗

Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.